ArticleFrontiers in oncology2026

Efficacy analysis of disitamab vedotin (RC-48) in the treatment of HER2-low metastatic breast cancer: a case report.

Ruiyue Wu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.